Abstract | BACKGROUND: METHODS: We conducted a phase 3 open-label, controlled trial to assess the efficacy and safety of pegcetacoplan as compared with eculizumab in adults with PNH and hemoglobin levels lower than 10.5 g per deciliter despite eculizumab therapy. After a 4-week run-in phase in which all patients received pegcetacoplan plus eculizumab, we randomly assigned patients to subcutaneous pegcetacoplan monotherapy (41 patients) or intravenous eculizumab (39 patients). The primary end point was the mean change in hemoglobin level from baseline to week 16. Additional clinical and hematologic markers of hemolysis and safety were assessed. RESULTS: CONCLUSIONS:
|
Authors | Peter Hillmen, Jeff Szer, Ilene Weitz, Alexander Röth, Britta Höchsmann, Jens Panse, Kensuke Usuki, Morag Griffin, Jean-Jacques Kiladjian, Carlos de Castro, Hisakazu Nishimori, Lisa Tan, Mohamed Hamdani, Pascal Deschatelets, Cedric Francois, Federico Grossi, Temitayo Ajayi, Antonio Risitano, Régis Peffault de la Tour |
Journal | The New England journal of medicine
(N Engl J Med)
Vol. 384
Issue 11
Pg. 1028-1037
(03 18 2021)
ISSN: 1533-4406 [Electronic] United States |
PMID | 33730455
(Publication Type: Clinical Trial, Phase III, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2021 Massachusetts Medical Society. |
Chemical References |
- Antibodies, Monoclonal, Humanized
- Complement C3
- Complement C5
- Complement Inactivating Agents
- Hemoglobins
- Peptides
- Peptides, Cyclic
- eculizumab
- pegcetacoplan
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal, Humanized
(adverse effects, therapeutic use)
- Complement C3
(antagonists & inhibitors)
- Complement C5
(antagonists & inhibitors)
- Complement Inactivating Agents
(adverse effects, therapeutic use)
- Diarrhea
(chemically induced)
- Drug Therapy, Combination
- Erythrocyte Transfusion
- Hemoglobins
(analysis)
- Hemoglobinuria, Paroxysmal
(blood, drug therapy, therapy)
- Humans
- Injections, Subcutaneous
(adverse effects)
- Middle Aged
- Peptides
(adverse effects, therapeutic use)
- Peptides, Cyclic
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|